Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Is Cdc25 a druggable target?

Literature DB >> 19075566

Is Cdc25 a druggable target?

Abstract

Proper control of cell cycle progression requires the functionality of a small family of activating phosphatases termed Cdc25, which have been implicated in cancer and Alzheimer's disease. These protein tyrosine phosphatases are therefore recognized as attractive molecular targets for small molecules. We review the rationale, approaches, progress and challenges for developing small molecule inhibitors of the Cdc25 family. A number of potential chemical probes are discussed and their characteristics are summarized.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 19075566 PMCID： PMC2752834 DOI： 10.2174/187152008786847738

Source DB: PubMed Journal: Anticancer Agents Med Chem ISSN： 1871-5206 Impact factor: 2.505

49 in total

1. Pharmacological rescue of mutant p53 conformation and function.

Authors: B A Foster; H A Coffey; M J Morin; F Rastinejad
Journal: Science Date: 1999-12-24 Impact factor: 47.728

2. Cdc25B functions as a novel coactivator for the steroid receptors.

Authors: Z Q Ma; Z Liu; E S Ngan; S Y Tsai
Journal: Mol Cell Biol Date: 2001-12 Impact factor: 4.272

3. Hypoxic suppression of the cell cycle gene CDC25A in tumor cells.

Authors: Stefanie Hammer; Kenneth K-W To; Young-Gun Yoo; Minori Koshiji; L Eric Huang
Journal: Cell Cycle Date: 2007-05-27 Impact factor: 4.534

4. Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase.

Authors: H Peng; W Xie; D M Otterness; J P Cogswell; R T McConnell; H L Carter; G Powis; R T Abraham; L H Zalkow
Journal: J Med Chem Date: 2001-03-01 Impact factor: 7.446

Review 5. Role of quinones in toxicology.

Authors: J L Bolton; M A Trush; T M Penning; G Dryhurst; T J Monks
Journal: Chem Res Toxicol Date: 2000-03 Impact factor: 3.739

6. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.

Authors: J S Lazo; D C Aslan; E C Southwick; K A Cooley; A P Ducruet; B Joo; A Vogt; P Wipf
Journal: J Med Chem Date: 2001-11-22 Impact factor: 7.446

7. The solid phase synthesis of tetrahydroisoquinolines having cdc25B inhibitory activity.

Authors: E L Fritzen; A S Brightwell; L A Erickson; D L Romero
Journal: Bioorg Med Chem Lett Date: 2000-04-03 Impact factor: 2.823

Review 8. What's new on CDC25 phosphatase inhibitors.

Authors: Marie-Odile Contour-Galcera; Alban Sidhu; Grégoire Prévost; Dennis Bigg; Bernard Ducommun
Journal: Pharmacol Ther Date: 2007-04-21 Impact factor: 12.310

Review 9. Targeting protein tyrosine phosphatase to enhance insulin action for the potential treatment of diabetes.

Authors: Bhavani Kasibhatla; John Wos; Kevin G Peters
Journal: Curr Opin Investig Drugs Date: 2007-10

Review 10. Evaluation of HIF-1 inhibitors as anticancer agents.

Authors: Gregg L Semenza
Journal: Drug Discov Today Date: 2007-09-18 Impact factor: 7.851

11 in total

1. A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.

Authors: Yongsheng Wu; Xiaoling Feng; Yucui Jin; Zhaojia Wu; William Hankey; Carolyn Paisie; Lei Li; Fengjuan Liu; Sanford H Barsky; Weiwei Zhang; Ramesh Ganju; Xianghong Zou
Journal: Cancer Prev Res (Phila) Date: 2010-06-29

Review 2. Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors: Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal: Curr Pharm Des Date: 2010-06 Impact factor: 3.116

Review 3. The role of Cdc25A in the regulation of cell proliferation and apoptosis.

Authors: Tao Shen; Shile Huang
Journal: Anticancer Agents Med Chem Date: 2012-07 Impact factor: 2.505

4. CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples.

Authors: Yoji Yamashita; Isao Kasugai; Masami Sato; Nobuhiro Tanuma; Ikuro Sato; Miyuki Nomura; Katsumi Yamashita; Yukihiko Sonoda; Toshihiro Kumabe; Teiji Tominaga; Ryuichi Katakura; Hiroshi Shima
Journal: J Neurooncol Date: 2010-03-10 Impact factor: 4.130

5. G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2).

Authors: Kaoru Nemoto
Journal: Exp Ther Med Date: 2010-07-01 Impact factor: 2.447

6. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.

Authors: Tatyana V Masyuk; Brynn N Radtke; Angela J Stroope; Jesús M Banales; Anatoliy I Masyuk; Sergio A Gradilone; Gabriella Bedekovicsne Gajdos; Natasha Chandok; Jason L Bakeberg; Christopher J Ward; Erik L Ritman; Hiroaki Kiyokawa; Nicholas F LaRusso
Journal: Gastroenterology Date: 2011-12-07 Impact factor: 22.682